Early Access — free while we kick the tires
EdgarHawk

Fenimore Christopher R.

SVP Finance & CFO

Officer
1 filing analyzed · 1 company · Latest 2024-08-29

Companies

Company Buys Sells Direction
REGENERON PHARMACEUTICALS, INC. REGN 0 10 Net selling

Activity

August 2024
Sell
5,680 shares
$6,846,262
Significance 5/10

CFO Fenimore sells 5,680 shares (99.6% of holdings) for $6.8M, reducing stake to 25 shares

Christopher R. Fenimore, SVP Finance & CFO, executed 10 separate sales on 2024-08-28 totaling 5,680 shares for $6,846,262.22, reducing his holdings from 5,705 shares to just 25 shares—a near-complete exit of his position. The blended average sale price of $1,205.33 occurred within the 52-week range ($775.18–$1,201.76) and 1.9% below the 52-week high. At his prior REGN sales on 2024-02-09, 0 of 5 prior sells were well-timed at the 90-day mark, with all five resulting in modest positive 90-day returns (ranging 1.4%–1.8%), meaning the stock rose after his prior exits. The scale and breadth of this liquidation—virtually eliminating executive ownership—deserves scrutiny, particularly given Regeneron's solid near-term fundamentals (FY revenue growth +7.8%, P/E 25.63) and the stock's strong recent momentum (+9.4% in 30 days, +20.3% in 90 days). Investors should monitor whether this represents a strategic shift in the CFO's equity commitment or reflects other considerations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access